U.S. BioDefense to Sponsor ``Business of Stem Cell Research'' Conference Produced by The Technology Council of Maryland and Leading Health Care Law Firm Arent Fox

CITY OF INDUSTRY, Calif.--(BUSINESS WIRE)--April 11, 2005--U.S. BioDefense, Inc. (OTCBB:UBDEE) CEO David Chin is pleased to announce today that it will sponsor the "Business of Stem Cell Research" Conference, produced by The Technology Council of Maryland and leading health care law firm Arent Fox.

The Business of Stem Cell Research Conference will be held on April 25, 2005 at the Marriott Bethesda North Hotel & Conference Center in Rockville, Maryland, the first forum to bring together C-Level executives from industry, politics, academia and science to discuss the promise of stem cell research from a business perspective. This daylong forum will cover:

“As U.S. BioDefense strives to be the leader in Stem Cell innovation, we are proud to be part of this unique event that will bring together potential collaborators and further advance Stem Cell Research”

-- The business potential of stem cell research

-- The state of the science

-- How pending legislation throughout the country will impact future funding and business

-- Who's funding the research and how to qualify for the research dollars

-- The crucial tools, technology and software infrastructure needed for the research now and in the future

-- Successful stem cell research business plans and case studies

"This conference will be the best resource for business people, academicians, scientists and the media to learn about the business of stem cell research in one-place-at-one-time," said Julie Coons, President of the Tech Council of Maryland.

"As U.S. BioDefense strives to be the leader in Stem Cell innovation, we are proud to be part of this unique event that will bring together potential collaborators and further advance Stem Cell Research," said David Chin, CEO.

About TCM

The Technology Council of Maryland is a not-for-profit membership organization that represents the interests of technology companies and brings together with other allied private sector businesses, the Educational Institutions and Federal Research Agencies, making up Maryland's technology community. The Technology Council of Maryland is organized to serve the State's technology community through two major Industry Networks, the Maryland BioScience Alliance (also known as the BioAlliance) and the Maryland IT and Advanced Technology Network. Along with the industry networks, peer groups are active such as the Financial Executives Forum, CIO Series, Technology Horizon Series and Federal Marketplace Series. Additionally, the Council hosts Regional Technology Networks in Frederick, Howard, Montgomery and Prince George's Counties, each active with their own programs and identities. Functionally, the Council is directed by a number of committees and task groups that include the Executive Committee and Board of Directors, Government Relations, the Program Committee, and the Membership Committee also known as the TechPack. The Council works closely with the Maryland Department of Economic Development, and many other technology and business interested organizations in the region. The Council periodically hosts Special events that bring together community leaders, and advances initiatives that build relationships in the technology community and with elected officials and government leaders.

About U.S. BioDefense, Inc.

U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. Please visit the company's web site for more information and a new white paper on Stem Cell technology transfer, analyzing California university and industry participants' intellectual property resources including ViaCell, Geron, Aastrom Biosciences and StemCells, Inc.

Safe Harbor Statement Forward-Looking Statements

Included in this release are certain "forward-looking" statements involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense's financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.